Published in Drugs Aging on January 01, 2007
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer (2008) 3.19
Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer (2014) 0.96
Developments in metastatic pancreatic cancer: is gemcitabine still the standard? World J Gastroenterol (2012) 0.94
Meta-analyses of treatment standards for pancreatic cancer. Mol Clin Oncol (2015) 0.79
Treatment of pancreatic cancer: what can we really predict today? Cancers (Basel) (2011) 0.76
Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Chin J Cancer (2014) 0.75
Pancreatic cancer. BMJ Clin Evid (2010) 0.75
Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis. World J Surg Oncol (2016) 0.75
A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial. BMC Cancer (2015) 0.75
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med (2009) 22.23
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res (2006) 13.98
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med (2006) 12.90
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol (2003) 12.82
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol (2008) 10.29
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol (2011) 8.66
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer (2010) 7.25
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol (2009) 5.45
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27
Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA (2010) 5.04
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol (2011) 4.77
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol (2006) 4.42
Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial. Lancet Neurol (2008) 4.12
Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. Lancet (2010) 4.07
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol (2013) 3.79
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol (2008) 3.49
Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol (2006) 3.46
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA (2004) 3.35
The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation (2008) 3.30
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol (2009) 3.18
Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg (2006) 3.05
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol (2013) 2.94
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer (2012) 2.79
Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med (2002) 2.76
Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med (2004) 2.64
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol (2013) 2.52
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer (2006) 2.51
Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J (2008) 2.51
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol (2005) 2.50
Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem (2013) 2.45
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg (2012) 2.43
PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res (2012) 2.43
Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke: a systematic review and meta-analysis. Stroke (2005) 2.38
Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol (2005) 2.38
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol (2011) 2.26
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology (2004) 2.16
Masked hypertension: a systematic review. J Hypertens (2008) 2.10
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol (2012) 2.07
[5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer]. Gastroenterol Clin Biol (2002) 2.04
The Framingham prediction rule is not valid in a European population of treated hypertensive patients. J Hypertens (2002) 2.03
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol (2008) 1.97
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst (2013) 1.90
Primary colectomy in patients with stage IV colon cancer and unresectable distant metastases improves overall survival: results of a multicentric study. Dis Colon Rectum (2011) 1.82
Integrating clinical research with the Healthcare Enterprise: from the RE-USE project to the EHR4CR platform. J Biomed Inform (2011) 1.81
Pulmonary resection for metastases of colorectal adenocarcinoma. Ann Thorac Surg (2010) 1.76
The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist (2012) 1.76
Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab (2005) 1.75
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology (2012) 1.67
Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. Eur Urol (2008) 1.66
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol (2011) 1.64
Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study. J Nucl Med (2011) 1.62
Pulmonary nodules: preliminary experience with three-dimensional evaluation. Radiology (2004) 1.62
Serial left ventricular adaptations in world-class professional cyclists: implications for disease screening and follow-up. J Am Coll Cardiol (2004) 1.61
Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension. Nephrol Dial Transplant (2004) 1.61
Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol (2010) 1.60
Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens (2012) 1.59
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer (2007) 1.58
The biological meaning of anti-HBC positive result in blood donors: relation to HBV-DNA and to other serological markers. Rev Inst Med Trop Sao Paulo (2003) 1.56
Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: early and 6 months follow-up. Eur Heart J (2008) 1.54
OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol (2005) 1.52
Predictive factors for masked hypertension within a population of controlled hypertensives. J Hypertens (2006) 1.51
Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res (2004) 1.51
Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment. Int J Colorectal Dis (2009) 1.50
Angiogenic growth factors and/or cellular therapy for myocardial regeneration: a comparative study. J Thorac Cardiovasc Surg (2004) 1.49
Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res (2006) 1.49
Chemotherapy in elderly patients with colorectal cancer. Oncologist (2008) 1.48
The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood (2008) 1.48
Systematic review and meta-analysis of strategies for the diagnosis of suspected pulmonary embolism. BMJ (2005) 1.44
The European experience with double-balloon enteroscopy: indications, methodology, safety, and clinical impact. Gastrointest Endosc (2005) 1.41
A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother (2010) 1.40
Predictive and discriminating three-risk-group prognostic scoring system for staging Hodgkin lymphomas. Cancer (2007) 1.40
The ratio of metastatic to examined lymph nodes is a powerful independent prognostic factor in rectal cancer. Ann Surg (2008) 1.39
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol (2013) 1.38
Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. Eur J Cancer (2010) 1.30
Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study. J Clin Oncol (2011) 1.29
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. J Natl Cancer Inst (2013) 1.28
Software volumetric evaluation of doubling times for differentiating benign versus malignant pulmonary nodules. AJR Am J Roentgenol (2006) 1.28
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst (2013) 1.27
Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer (2002) 1.24
Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol (2009) 1.24
Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer (2013) 1.24
Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening. Am J Gastroenterol (2008) 1.20
The readability of information and consent forms in clinical research in France. PLoS One (2010) 1.19
Socioeconomic inequalities in hypertension prevalence and care: the IHPAF Study. Hypertension (2002) 1.18
Pancreatic metastases: a multicentric study of 22 patients. Gastroenterol Clin Biol (2004) 1.18
Influenza-like illness responsible for severe exacerbations in asthmatic children during H1N1 pandemic: a survey before vaccination. J Asthma (2011) 1.17